Methsuximide | CAS#77-41-8

MedKoo Cat#: 318204 | Name: Methsuximide

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mesuximide is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin and Celontin. The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.

Chemical Structure

Methsuximide

CAS#77-41-8

Theoretical Analysis

MedKoo Cat#: 318204

Name: Methsuximide

CAS#: 77-41-8

Chemical Formula: C12H13NO2

Exact Mass: 203.0946

Molecular Weight: 203.24

Elemental Analysis: C, 70.92; H, 6.45; N, 6.89; O, 15.74

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 300.00	2 weeks
100mg	USD 660.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Methsuximide; Mesuximide; Celontin; Petinutin; Mesuximidum; Methsuximid; (±)-Mesuximide; N,2-dimethyl-2-Phenylsuccinimide; PM 396

IUPAC/Chemical Name

1,3-dimethyl-3-phenylpyrrolidine-2,5-dione

InChi Key

AJXPJJZHWIXJCJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3

SMILES Code

O=C(C(C1=CC=CC=C1)(C)C2)N(C)C2=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Methsuximide is an anticonvulsant agent.

In vitro activity:

TBD

In vivo activity:

TBD

	Solvent	mg/mL	mM
Solubility
	DMF	25.0	123.01
	DMSO	30.0	147.61
	DMSO:PBS (pH 7.2) (1:40)	0.0	0.10
	Ethanol	25.0	123.01

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 203.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

TBD

In vitro protocol:

TBD

In vivo protocol:

TBD

1: Sigler M, Strassburg HM, Boenigk HE. Effective and safe but forgotten: methsuximide in intractable epilepsies in childhood. Seizure. 2001 Mar;10(2):120-4. PubMed PMID: 11407955. 2: Blakely E, Starin S, Poling A. Effects of mephenytoin and methsuximide on the reaction time of pigeons. Pharmacol Biochem Behav. 1988 Dec;31(4):787-90. PubMed PMID: 3252269. 3: Schlinger H, Wilkenfield J, Poling A. Effects of methsuximide and mephenytoin on the responding of pigeons under a fixed-consecutive-number schedule with and without an external discriminative stimulus. Psychopharmacology (Berl). 1988;95(2):216-21. PubMed PMID: 3137600. 4: Schlinger H, Poling A. Acute and chronic effects of methsuximide and mephenytoin on the delayed-matching-to-sample performance of pigeons. Psychopharmacology (Berl). 1988;95(1):82-6. PubMed PMID: 3133702. 5: Sklenovský A, Chmela Z. The effect of antiepileptic drugs. II. (Valproate, methsuximide) on nonesterified fatty acids in the brain structures during convulsive state. Acta Univ Palacki Olomuc Fac Med. 1987;117:125-35. PubMed PMID: 2963488. 6: Browne TR, Feldman RG, Buchanan RA, Allen NC, Fawcett-Vickers L, Szabo GK, Mattson GF, Norman SE, Greenblatt DJ. Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology. 1983 Apr;33(4):414-8. PubMed PMID: 6403891. 7: Strong JM, Abe T, Gibbs EL, Atkinson AJ Jr. Plasma levels of methsuximide and N-desmethylmethsuximide during methsuximide therapy. Neurology. 1974 Mar;24(3):250-5. PubMed PMID: 4855951. 8: Horning MG, Butler C, Harvey DJ, Hill RM, Zion TE. Metabolism of N,2-dimethyl-2-phenylsuccinimide (methsuximide) by the epoxide-diol pathway in rat, guinea pig and human. Res Commun Chem Pathol Pharmacol. 1973 Sep;6(2):565-78. PubMed PMID: 4750102. 9: Karch SB. Methsuximide overdose. Delayed onset of profound coma. JAMA. 1973 Mar 26;223(13):1463-5. PubMed PMID: 4740029. 10: Orton TC, Nicholls PJ. Effect in rats of subacute administration of ethosuximide, methsuximide and phensuximide on hepatic microsomal enzymes and porphyrin turnover. Biochem Pharmacol. 1972 Aug 15;21(16):2253-61. PubMed PMID: 4646191. 11: Orton TC, Nicholls PJ. Porphyrogenic activity of methsuximide and its demethylated metabolite. J Pharm Pharmacol. 1972 Feb;24(2):151-2. PubMed PMID: 4401970. 12: STEIN S, PEMBROOK RC. CROSS-SENSITIVITY TO DILANTIN (DIPHENYLBYDANTOIN) AND CELONTIN (METHSUXIMIDE). J Pediatr. 1965 Apr;66:799-801. PubMed PMID: 14271375. 13: CHEN G, WESTON JK, BRATTON AC Jr. Anticonvulsant activity and toxicity of phensuximide, methsuximide and ethosuximide. Epilepsia. 1963 Mar;4:66-76. PubMed PMID: 14020499. 14: Besag FM, Berry DJ, Vasey M. Methsuximide reduces valproic acid serum levels. Ther Drug Monit. 2001 Dec;23(6):694-7. PubMed PMID: 11802106. 15: Besag FM, Berry DJ, Pool F. Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000 May;41(5):624-7. PubMed PMID: 10802770. 16: Wad N, Bourgeois B, Krämer G. Serum protein binding of desmethyl-methsuximide. Clin Neuropharmacol. 1999 Jul-Aug;22(4):239-40. PubMed PMID: 10442255. 17: May TW, Rambeck B, Jürgens U. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit. 1999 Apr;21(2):175-81. PubMed PMID: 10217337. 18: Hurst DL. Methsuximide therapy of juvenile myoclonic epilepsy. Seizure. 1996 Mar;5(1):47-50. PubMed PMID: 8777552. 19: Dooley J, Camfield P, Buckley D, Gordon K, Wirrell E, Camfield C. Methsuximide-induced movement disorder. Pediatrics. 1991 Dec;88(6):1291-2. PubMed PMID: 1956755. 20: Tennison MB, Greenwood RS, Miles MV. Methsuximide for intractable childhood seizures. Pediatrics. 1991 Feb;87(2):186-9. PubMed PMID: 1987529.